Microtubule-targeting drugs work everywhere except the brain.
Microtubule-targeting therapies have successfully treated breast, lung, ovarian, thyroid, and prostate cancers…but not brain tumors.
How tubulin therapy works
The tubulin protein polymerizes to form microtubules, the molecular highways that shuttle materials from one part of a cell to another. When microtubule formation is disrupted, cancer cells arrest during the replication cycle and die.
What makes RGN6024 different
Safety First
Most cancer therapies are given intravenously in a clinical setting and carry significant side effects. RGN6024 is an oral, twice-daily medicine designed to be taken at home.
Blood-Brain Barrier (BBB) Penetrant
Only about 2% of marketable drugs cross the blood-brain barrier, the filter that keeps toxins and medicines out of the brain. RGN6024 crosses it and reaches nearly the same concentration in the brain as in peripheral blood.
Well-Validated Target
RGN6024 targets tubulin, one of the most validated targets in the history of cancer therapy, and one that has been out of reach in the brain because of the blood-brain barrier. Many drugs and delivery systems have tried to deliver microtubule-targeting therapies to the brain and failed.
Medicines for a Global Market
RGN6024 is a small molecule. That means oral administration, low manufacturing cost, and a well-traveled development and regulatory path.